Last reviewed · How we verify
HC010
At a glance
| Generic name | HC010 |
|---|---|
| Sponsor | HC Biopharma Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Phase Ib Clinical Study on the Safety and Efficacy of HC010 Combinations in Advanced Solid Tumors (PHASE1)
- A Phase Ib Clinical Study on the Safety and Efficacy of HC010 Combined With Chemotherapy in Lung Cancer (PHASE1)
- HC010 in First-line PD-L1 Positive Advanced NSCLC Patients (PHASE2)
- A Phase I Study to Evaluate the Safety, Pharmacokinetics and Antitumor Activity of HC010 in Patients With Advanced Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HC010 CI brief — competitive landscape report
- HC010 updates RSS · CI watch RSS
- HC Biopharma Inc. portfolio CI